Breaking News, Financial News

Financial Report: Alkermes

Revenues up 14% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alkermes 3Q Revenues: $160.0 million (+14%)   3Q Loss: $40.0 million (loss of $7.8 million 3Q13)   YTD Revenues: $443.6 million (flat)   YTD Loss: $60.6 million (earnings were $2.6 million YTD13)   Comments: Manufacturing and royalty revenues for the long-acting atypical antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION, were $68.5 million in the quarter, up 9%. Manufacturing and royalty revenues from AMPYRA/FAMPYRAwere $16.5 million, up 31%. Sales of VIVITROL were $25.8 mil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters